It's been an exciting year so far for biotech acquisitions: Perrigo made a surprising move for Elan, AstraZeneca has been boosting its pipeline with a series of purchases, and Amgen's recent buyout of oncology specialist Onyx revived investor enthusiasm in the second biggest biotech company in the world. And it doesn't look like this trend is going to stop any time soon.
At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG) and pharmaceutical giant Sanofi (SNY 6.63%) may be circling ViroPharma (NASDAQ: VPHM). The the following video, from The Motley Fool's health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.
